Abstract
TSC-22 (Transforming growth factor-β stimulated clone-22) was originally isolated as a TGF-β- inducible gene in mouse osteoblastic cells. TSC-22 encodes a putative transcriptional regulator containing a leucine zipper-like structure. Several differentiation-inducing stimuli up-regulate the TSC-22 gene. Furthermore, TSC-22 acts as an effector that integrates multiple extracellular signals during embryogenesis of Drosophila and mouse. Separately, we identified TSC-22 cDNA as an anti-cancer drug (vesnarinone)-inducible gene in a human salivary gland cancer cell line, TYS. Vesnarinone is known to have a differentiation-inducing activity in several cell types. We showed that TSC-22 negatively regulated the growth of TYS cells, and that down-regulation of TSC-22 played a major role in the salivary gland tumorigenesis. Subsequently, we found that artificial overexpression of TSC-22 enhanced chemosensitivity and radiation-sensitivity by inducing apoptosis in TYS cells. Recently, we isolated TSC-22 genomic DNA and analyzed the transcriptional and posttranscriptional regulation of the TSC-22 gene. Then, we confirmed by the luciferase reporter assay that several differentiation-inducing stimuli directly activated the promoter region of TSC-22 gene. Now we are investigating the chemical compounds, which could enhance the transcription of the TSC-22 gene. Thus, because TSC-22 is a key molecule for differentiation of several cells, it can be used as a molecular target for cancer differentiation therapy in salivary gland cancer.
Keywords: differentiation therapy, salivary gland cancer, molecular target, radiation-sensitivit
Current Cancer Drug Targets
Title: TSC-22 (TGF-β Stimulated Clone-22): A Novel Molecular Target for Differentiation-Inducing Therapy in Salivary Gland Cancer
Volume: 4 Issue: 6
Author(s): H. Kawamata, T. Fujimori and Y. Imai
Affiliation:
Keywords: differentiation therapy, salivary gland cancer, molecular target, radiation-sensitivit
Abstract: TSC-22 (Transforming growth factor-β stimulated clone-22) was originally isolated as a TGF-β- inducible gene in mouse osteoblastic cells. TSC-22 encodes a putative transcriptional regulator containing a leucine zipper-like structure. Several differentiation-inducing stimuli up-regulate the TSC-22 gene. Furthermore, TSC-22 acts as an effector that integrates multiple extracellular signals during embryogenesis of Drosophila and mouse. Separately, we identified TSC-22 cDNA as an anti-cancer drug (vesnarinone)-inducible gene in a human salivary gland cancer cell line, TYS. Vesnarinone is known to have a differentiation-inducing activity in several cell types. We showed that TSC-22 negatively regulated the growth of TYS cells, and that down-regulation of TSC-22 played a major role in the salivary gland tumorigenesis. Subsequently, we found that artificial overexpression of TSC-22 enhanced chemosensitivity and radiation-sensitivity by inducing apoptosis in TYS cells. Recently, we isolated TSC-22 genomic DNA and analyzed the transcriptional and posttranscriptional regulation of the TSC-22 gene. Then, we confirmed by the luciferase reporter assay that several differentiation-inducing stimuli directly activated the promoter region of TSC-22 gene. Now we are investigating the chemical compounds, which could enhance the transcription of the TSC-22 gene. Thus, because TSC-22 is a key molecule for differentiation of several cells, it can be used as a molecular target for cancer differentiation therapy in salivary gland cancer.
Export Options
About this article
Cite this article as:
Kawamata H., Fujimori T. and Imai Y., TSC-22 (TGF-β Stimulated Clone-22): A Novel Molecular Target for Differentiation-Inducing Therapy in Salivary Gland Cancer, Current Cancer Drug Targets 2004; 4 (6) . https://dx.doi.org/10.2174/1568009043332844
DOI https://dx.doi.org/10.2174/1568009043332844 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nitric Oxide-Releasing Biomaterials for Biomedical Applications
Current Medicinal Chemistry Targeting the NF-κB pathway in prostate cancer: a promising therapeutic approach?
Current Drug Targets Identification of Biomarkers and Functional Modules from Genomic Data in Stage-wise Breast Cancer
Current Bioinformatics Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas
Current Cancer Drug Targets Perspectives of Fullerenes, Dendrimers, and Heterocyclic Compounds Application in Tumor Treatment
Recent Patents on Nanomedicine Beyond the "Lock and Key" Paradigm: Targeting Lipid Rafts to Induce the Selective Apoptosis of Cancer Cells
Current Medicinal Chemistry Last Generation of Amino-Bisphosphonates (N-BPs) and Cancer Angiogenesis: A New Role for These Drugs?
Recent Patents on Anti-Cancer Drug Discovery Editorial [Hot Topic: Modulation, Absorption and Delivery of Xenobiotics: The Synergic Role of CYP450 and P-gp Activities (Guest Editor: Nicola Antonio Colabufo)]
Current Drug Metabolism Melanoma Immunotherapy: Past, Present, and Future
Current Pharmaceutical Design Embryonic Stem Cells: Overcoming the Immunological Barriers to Cell Replacement Therapy
Current Stem Cell Research & Therapy Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Mechanism of Anti-Tumor Effect by Curcumin in Hematological Malignancies
Current Pharmaceutical Analysis An Update on Natural Occurrence and Biological Activity of Chromones
Current Medicinal Chemistry Anti-cancer Drug Delivery Using Metal Organic Frameworks (MOFs)
Current Medicinal Chemistry Prodrug Design of Phenolic Drugs
Current Pharmaceutical Design Polymeric Nanocarriers: A New Horizon for the Effective Management of Breast Cancer
Current Pharmaceutical Design New Opportunities for Pregnane X Receptor (PXR) Targeting in Drug Development. Lessons from Enantio- and Species-Specific PXR Ligands Identified from A Discovery Library of Amino Acid Analogues
Mini-Reviews in Medicinal Chemistry Potential Use of Polymeric Nanoparticles for Drug Delivery Across the Blood-Brain Barrier
Current Medicinal Chemistry Low Dose Aspirin, COX-Inhibition and Chemoprevention of Colorectal Cancer
Current Topics in Medicinal Chemistry Interactions of Cisplatin with non-DNA Targets and their Influence on Anticancer Activity and Drug Toxicity: The Complex World of the Platinum Complex
Current Cancer Drug Targets